Bone mineral density in HIV participants randomized to raltegravir and lopinavirritonavir compared with standard second line therapy

Authors :: Martin, Allison
Moore, Cecilia
Mallon, Patrick W.G.
Hoy, Jennifer
Emery, Sean
Belloso, Waldo
Phanuphak, Praphan
Ferret, Samuel
Cooper, David A.
Boyd, Mark A.
Source :: AIDS; September 2013, Vol. 27 Issue: 15 p2403-2411, 9p
Publication Year :: 2013
Abstract: To compare changes over 48 weeks in bone mineral density (BMD) between participants randomized to lopinavirritonavir (LPVr)raltegravir (RAL) or LPVr 2–3nucleosidenucleotide reverse transcriptase inhibitors (N(t)RTIs) as second line therapy.

Full Text Access

Tools